Showing results (231-240 of 322) with videos related to
Sort By:
Pageof 33
The New England Journal of Medicine|April 28, 1994
Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantationE B Papadopoulos, M Ladanyi, D Emanuel, et al.Blood|January 29, 2000
Epstein-Barr virus (EBV) load in bone marrow transplant recipients at risk to develop posttransplant lymphoproliferative disease: prophylactic infusion of EBV-specific cytotoxic T cellsA Gustafsson, V Levitsky, J Z Zou, et al.Bone Marrow Transplantation|December 12, 2002
A phase II trial of liposomal busulphan as an intravenous myeloablative agent prior to stem cell transplantation: 500 mg/m(2) as a optimal total dose for conditioningM Hassan, C Nilsson, Z Hassan, et al.British Journal of Haematology|October 1, 1993
Relapse of aplastic anaemia after immunosuppressive treatment: a report from the European Bone Marrow Transplantation Group SAA Working PartyH Schrezenmeier, P Marin, A Raghavachar, et al.Bone Marrow Transplantation|March 1, 1994
Graft rejection and second bone marrow transplants for acquired aplastic anaemia: a report from the Aplastic Anaemia Working Party of the European Bone Marrow Transplant GroupS R McCann, A Bacigalupo, E Gluckman, et al.Bone Marrow Transplantation|February 1, 1994
Cytomegalovirus interstitial pneumonia in autologous bone marrow transplant recipients. Infectious Disease Working Party of the European Group for Bone Marrow TransplantationP Ljungman, P Biron, A Bosi, et al.British Journal of Clinical Pharmacology|December 14, 1999
A mechanism-based pharmacokinetic-enzyme model for cyclophosphamide autoinduction in breast cancer patientsM Hassan, U S Svensson, P Ljungman, et al.Bone Marrow Transplantation|May 9, 2000
The effect of busulphan on the pharmacokinetics of cyclophosphamide and its 4-hydroxy metabolite: time interval influence on therapeutic efficacy and therapy-related toxicityM Hassan, P Ljungman, O Ringdén, et al.Blood|November 15, 1993
Outcome for patients who relapse after allogeneic bone marrow transplantation for chronic myeloid leukemia. Chronic Leukemia Working Party. European Bone Marrow Transplantation GroupW Arcese, J M Goldman, E D'Arcangelo, et al.Bone Marrow Transplantation|March 24, 2015
Evaluation of pretransplant influenza vaccination in hematopoietic SCT: a randomized prospective studyA Ambati, L S V Boas, P Ljungman, et al.Pageof 33